SCHEMBL19906479

SCHEMBL19906479

Cc1cc2c(cc1N)COC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.46
TSHR P16473 2/20 0.46
MAPK1 P28482 1/20 0.46
ALDH1A1 P00352 4/20 0.38
HSD17B10 Q99714 2/20 0.38
CYP1A2 P05177 1/20 0.38
ALOX15 P16050 1/20 0.38
CASP7 P55210 1/20 0.38
HIF1A Q16665 1/20 0.38
TERT O14746 1/20 0.37
TDP1 Q9NUW8 3/20 0.36
CASP1 P29466 1/20 0.36
IKBKB O14920 1/20 0.34
UHRF1 Q96T88 1/20 0.33
ATAD2 Q6PL18 1/20 0.33
PRKCG P05129 1/20 0.31
PRKCA P17252 1/20 0.31
PRKCD Q05655 1/20 0.31
CD44 P16070 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17864275 0.82 PTK2 (0.41) ALDH1A1TDP1IKBKBPRKCGPRKCA
SCHEMBL22271439 0.82 PRKCG (0.37) CYP3A4TSHRMAPK1IKBKBPRKCG
SCHEMBL3822542 0.78 ALDH1A1 (0.48) CYP3A4TSHRMAPK1ALDH1A1HSD17B10
SCHEMBL30604480 0.77 CYP3A4 (0.52) CYP3A4TSHRMAPK1ALDH1A1HSD17B10
SCHEMBL19995801 0.77 CYP3A4 (0.52) CYP3A4TSHRMAPK1ALDH1A1HSD17B10
SCHEMBL31393884 0.76 PRKCG (0.31) PRKCGPRKCAPRKCDPOLB
SCHEMBL19906482 0.76 MEN1 (0.35) ALDH1A1PRKCGPRKCAPRKCDPOLB
SCHEMBL19995809 0.73 ALDH1A1 (0.54) CYP3A4TSHRMAPK1ALDH1A1HSD17B10
SCHEMBL24823064 0.71 PRKCG (0.31) PRKCGPRKCAPRKCD
SCHEMBL22271443 0.71 PRKCG (0.35) TSHRPRKCGPRKCAPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210292283-A1 6-MEMBERED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SHIONOGI & CO., LTD. (JP) 2021-09-23 US disclosed
US-11124486-B2 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2021-09-21 US disclosed
US-10774051-B2 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same SHIONOGI & CO., LTD. (JP) 2020-09-15 US disclosed
EP-3686204-A1 THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2020-07-29 EP disclosed
US-20180118694-A1 6-MEMBERED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SHIONOGI & CO., LTD. (JP) 2018-05-03 US disclosed
US-20180118694-A1 6-MEMBERED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME SHIONOGI & CO., LTD. (JP) 2018-05-03 US disclosed
EP-3287443-A1 6-MEMBERED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Shionogi & Co., Ltd (JP) 2018-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118694-A1 6-MEMBERED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, C1S CYP3A4 155/4885TSHR 575/4885MAPK1 2659/4885
US-20210292283-A1 6-MEMBERED HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, C1S CYP3A4 169/4885TSHR 754/4885MAPK1 1988/4885
US-11124486-B2 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, C1S CYP3A4 131/4885TSHR 749/4885MAPK1 2793/4885
US-10774051-B2 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, C1S CYP3A4 155/4885TSHR 575/4885MAPK1 2659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.